Last reviewed · How we verify
NCT06751524
Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval
trial testing Botensilimab in Colorectal Cancer (CRC). Available.
Quick facts
| Lead sponsor | Agenus Inc. |
|---|---|
| Status | AVAILABLE |
| Study type | EXPANDED_ACCESS |
Drugs / interventions tested
- Botensilimab — full drug profile →
- Balstililmab — full drug profile →
Conditions studied
- Colorectal Cancer (CRC) — all drugs for Colorectal Cancer (CRC) →
- Pancreatic Cancer — all drugs for Pancreatic Cancer →
- Non-Small Cell Lung Cancer (NSCLC) — all drugs for Non-Small Cell Lung Cancer (NSCLC) →
- Hepatocellular Carcinoma (HCC) — all drugs for Hepatocellular Carcinoma (HCC) →
Sponsor
Agenus Inc. — full company profile →
Who can join
Eligibility, any sex, with Colorectal Cancer (CRC) or Pancreatic Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an expanded access program (EAP) designed to provide access to Botensilimab and Balstilimab prior to drug registration by the applicable local regulatory agency. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06751524
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Botensilimab
Trials testing the same drug.
- NCT07516366 — Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell R · Phase 2 · not yet recruiting
- NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
- NCT06346197 — Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas · Phase 3 · recruiting
- NCT06411691 — KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and · Phase 1 · recruiting
- NCT06843551 — The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation · Phase 2 · recruiting
Other recruiting trials for Colorectal Cancer (CRC)
Currently open trials in the same condition.
- NCT07448142 — Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer · Phase 2 · recruiting
- NCT07223047 — A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agent · Phase 1, PHASE2 · recruiting
- NCT07106892 — Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects Wit · Phase 2 · recruiting
- NCT07152210 — Clinical Study on the Safety and Preliminary Efficacy of CDH17/GUCY2C CAR-T in the Treatment of Patients With Advanced C · NA · recruiting
- NCT07046468 — Smart Pill for Measuring Gut Health in Colon Inflammation and Colon Cancer · recruiting
Other Agenus Inc. trials
Trials by the same sponsor.
- NCT05630183 — A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer · Phase 2 · active not recruiting
- NCT05377528 — Study of AGEN1571 in Participants With Advanced Solid Tumors · Phase 1 · completed
- NCT05025085 — A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors · Phase 1 · completed
- NCT05033132 — A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical Cancer · Phase 2 · withdrawn
- NCT04943627 — Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA) · Phase 3 · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06751524 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Agenus Inc.
- Last refreshed: 30 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06751524.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing